Literature DB >> 18849641

Describing peripancreatic collections in severe acute pancreatitis using morphologic terms: an international interobserver agreement study.

Hjalmar C van Santvoort1, Thomas L Bollen, Marc G Besselink, Peter A Banks, Marja A Boermeester, Casper H van Eijck, Jonathan Evans, Patrick C Freeny, Lars Grenacher, John J Hermans, Karen D Horvath, David M Hough, Johan S Laméris, Maarten S van Leeuwen, Koenraad J Mortele, John P Neoptolemos, Michael G Sarr, Santhi Swaroop Vege, Jens Werner, Hein G Gooszen.   

Abstract

BACKGROUND/AIMS: The current terminology for describing peripancreatic collections in acute pancreatitis (AP) derived from the Atlanta Symposium (e.g. pseudocyst, pancreatic abscess) has shown a very poor interobserver agreement, creating the potential for patient mismanagement. A study was undertaken to determine the interobserver agreement for a new set of morphologic terms to describe peripancreatic collections in AP.
METHODS: An international, interobserver agreement study was performed: 7 gastrointestinal surgeons, 2 gastroenterologists and 8 radiologists in 3 US and 5 European tertiary referral hospitals independently evaluated 55 computed tomography (CT) scans of patients with predicted severe AP. The percentage agreement [median, interquartile range (IQR)] for 9 clinically relevant morphologic terms was calculated among all reviewers, and separately among radiologists and clinicians. The percentage agreement was defined as poor (<0.50), moderate (0.51-0.70), good (0.71-0.90), and excellent (0.91-1.00).
RESULTS: Overall agreement was good to excellent for the terms collection (percentage agreement = 1; IQR 0.68-1), relation with pancreas (1; 0.68-1), content (0.88; 0.87-1), shape (1; 0.78-1), mass effect (0.78; 0.62-1), loculated gas bubbles (1; 1-1), and air-fluid levels (1; 1-1). Overall agreement was moderate for extent of pancreatic nonenhancement (0.60; 0.46-0.88) and encapsulation (0.56; 0.48-0.69). The percentage agreement was greater among radiologists than clinicians for extent of pancreatic nonenhancement (0.75 vs. 0.57, p = 0.008), encapsulation (0.67 vs. 0.46, p = 0.001), and content (1 vs. 0.78, p = 0.008).
CONCLUSION: Interobserver agreement for the new set of morphologic terms to describe peripancreatic collections in AP is good to excellent. Therefore, we recommend that current clinically based definitions for CT findings in AP (e.g. pancreatic abscess) should no longer be used. Copyright 2008 S. Karger AG, Basel and IAP.

Entities:  

Mesh:

Year:  2008        PMID: 18849641     DOI: 10.1159/000161010

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  5 in total

1.  Revising the Atlanta classification of acute pancreatitis: festina lente.

Authors:  Maxim S Petrov
Journal:  J Gastrointest Surg       Date:  2010-06-29       Impact factor: 3.452

Review 2.  Early management of severe acute pancreatitis.

Authors:  Rupjyoti Talukdar; Santhi Swaroop Vege
Journal:  Curr Gastroenterol Rep       Date:  2011-04

3.  A Rare Cause of Acute Upper Gastrointestinal Hemorrhage.

Authors:  T S de Vries Reilingh; V A Postma; T J Aufenacker; L J A Strobbe; C Rosman
Journal:  Case Rep Gastroenterol       Date:  2009-11-21

Review 4.  Prevention, detection, and management of infected necrosis in severe acute pancreatitis.

Authors:  Olaf J Bakker; Hjalmar C van Santvoort; Marc G H Besselink; Erwin van der Harst; H Sijbrand Hofker; Hein G Gooszen
Journal:  Curr Gastroenterol Rep       Date:  2009-04

5.  Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: an international expert survey and case vignette study.

Authors:  Janneke van Grinsven; Sandra van Brunschot; Olaf J Bakker; Thomas L Bollen; Marja A Boermeester; Marco J Bruno; Cornelis H Dejong; Marcel G Dijkgraaf; Casper H van Eijck; Paul Fockens; Harry van Goor; Hein G Gooszen; Karen D Horvath; Krijn P van Lienden; Hjalmar C van Santvoort; Marc G Besselink
Journal:  HPB (Oxford)       Date:  2015-12-20       Impact factor: 3.647

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.